Fried Robert N 4

What Happened

• Robert N. Fried, CEO of Niagen Bioscience (NAGE), acquired 1,106 shares on 2026-06-30 as an award/grant under the issuer's employee stock purchase plan. The shares were issued at $2.71 each for a total value of approximately $2,997. This is an acquisition/award (not a sale) and is generally a routine, compensation-related transaction rather than a market-timing trade.

Key Details

• Transaction date: 2026-06-30; Filing date (Form 4): 2026-07-08.
• Transaction type/code: Award/Grant (A); 1,106 shares @ $2.71 = $2,997.
• Plan: Shares were acquired pursuant to the issuer's Employee Stock Purchase Plan (footnote F1); the acquisition is exempt under Rule 16b-3(c) and 16b-3(d).
• Ownership after transaction: The Form 4 does not state Fried's beneficial ownership of these shares; the reporting person disclaims beneficial ownership of the securities (footnote F2). The filing notes family holdings: 6,745 shares held by Jeremy Fried and 6,001 shares held by Benjamin Fried (sons) (footnote F3).
• No indication in the filing that shares were immediately sold or that this was a cashless exercise.

Context

• This was a small, routine compensation/employee-plan award (≈$3k) rather than a buy/sell signaling large personal investment or divestment. Rule 16b-3 exemptions are standard for employee plan transactions and generally allow insiders to receive plan shares without short-swing profit exposure. Retail investors should view this as routine insider compensation activity, not necessarily a directional endorsement of the stock.